Newron Pharmaceuticals SpA (Newron) researches, discovers, develops, and commercializes novel drugs for the treatment of diseases related to the central nervous system (CNS) and pain. The company operates as a single business segment, which is the research and development of pharmaceutical drugs. Newron's marketed product, Xadago (safinamide), is an oral, unique molecule with a dual mechanism of action based on the inhibition of the excessive release of glutamate and enhancement of the dopaminergic function. The drug is developed as once-a-day adjunctive therapy for any stage of Parkinson's disease (PD).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company is came into partnership with Zambon and Supernus to further develop and market its product, Xadago. Its pipeline products include Evenamide(NW-3509) in Phase-III for the treatment of therapy in Schizophrenia and Ralfinamide in Phase II for the treatment of neuropathic pain. In FY2022, the company spent on R&D activities stood at EUR12.005 million.